Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hip fracture

Case Report: Rheumatoid Arthritis Complicated by Large Granular Lymphocytic Leukemia

Nam D. Nguyen, DO (Maj., USAF, MC), Erica Hill, DO (Lt. Col., USAF, MC), & Jay Higgs, MD (Col. [ret], USAF, MC)  |  November 14, 2021

Large granular lymphocytic (LGL) leukemia is a rare, chronic, lymphoproliferative disorder of cytotoxic T cell or natural killer cell lineage with an annual incidence of 0.72 cases per 1 million people in the U.S.1 The most common sub­type of LGL leukemia, T-LGL leukemia, follows an indolent disease course and accounts for approximately 85% of cases….

Filed under:ConditionsRheumatoid Arthritis Tagged with:large granular lymphocyte leukemiavertebral fracture

Untangling the Diagnosis & Management of GCA

Jason Liebowitz, MD, FACR  |  June 28, 2021

Vision loss, implications of treatment and more—Sarah Mackie, BMBCh, PhD, MRCP, discussed the latest research on the evaluation and management of giant cell arteritis.

Filed under:ConditionsEULAR/OtherMeeting ReportsVasculitis Tagged with:EULARGCAgiant cell arteritis (GCA)vision loss

4 ARP Members Talk About Their Roads to Advocacy & Why It Matters

From ARP Representatives to the ACR Government Affairs Committee  |  May 13, 2021

The Budget Control Act of 2011 cut Medicare physician payments by 2% across the board. The Coronavirus Aid, Relief, and Economic Security (CARES) Act, signed into law in 2020, suspended this sequester (i.e., a cut in government spending) between May 1 and Dec. 31, 2020. In the Consolidated Appropriations Act, signed into law in December…

Filed under:Interprofessional PerspectiveLegislation & Advocacy Tagged with:Association of Rheumatology Professionals (ARP)

Denosumab Has Edge on Alendronate for Steroid-Induced Bone Loss

Matthew Phelan  |  March 10, 2021

NEW YORK (Reuters Health)—Long-term glucocorticoid users see greater gains in spine bone-mineral density when treated with the monoclonal antibody denosumab vs. oral alendronate, a small clinical trial shows. The drug also proved superior at lowering bone-turnover markers at 12 months, researchers in Hong Kong report in Bone.1 “Denosumab may be considered as an alternative first-line…

Filed under:Drug Updates Tagged with:alendronatebone lossbone mineral density (BMD)denosumabGlucocorticoids

Therapeutic Exercise for Bone Health

Mary Beth Nierengarten  |  December 17, 2020

ACR CONVERGENCE 2020—Attention to bone health in people at risk of developing, or who already have, osteoporosis is essential to reduce their increased risk for fragility fractures. Major risk factors for osteoporosis include being female, white, of small frame and having a family history of osteoporosis, as well as having secondary causes of osteoporosis, such…

Filed under:ACR ConvergenceConditionsMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:ACR Convergence 2020boneExerciseexercise therapyOsteoporosispostmenopausalpremenopauseWomen

New Findings on Hydroxychloroquine, Denosumab

Ruth Jessen Hickman, MD  |  November 12, 2020

ACR Convergence 2020—At two plenary sessions, speakers highlighted key findings, including results on the QTc interval in patients on hydroxychloroquine, and data from a study on denosumab vs. alendronate for glucocorticoid-induced osteoporosis. The QTc Interval & Hydroxychloroquine The safety profile and optimal dosing of hydroxychloroquine has been a topic for decades because it is known…

Filed under:ACR ConvergenceConditionsDrug UpdatesMeeting ReportsOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:ACR Convergence 2020bone mineral density (BMD)COVID-19denosumabFracturesHydroxychloroquine (HCQ)Osteoporosis

A transverse view of the ulnar groove in full elbow extension. The red arrow indicates the advancing edge of the MHTr.

Recurrent Medial Elbow Pain Following Successful Tommy John Surgery

Mark H. Greenberg, MD, RMSK, RhMSUS, A. Lee Day, MD, RMSK, James W. Fant Jr., MD, & Christopher G. Mazoue, MD  |  August 12, 2020

A 27-year-old, left-handed man was referred to our ultrasound clinic for left elbow pain. History The patient had been a pitcher on a Minor League Baseball team. Two years before, he developed sudden, severe medial elbow pain while pitching in a game. The pain was associated with some tingling down the left medial forearm. The…

Filed under:Conditions Tagged with:case reportdiagnostic imagingelbow painTommy John Surgeryulnar nerveulnar nerve instabilityulnar nerve relocation syndromeultrasonographyUltrasound

Bisphosphonates Reduce Bone Toughness Over Time

Will Boggs, MD  |  August 11, 2020

NEW YORK (Reuters Health)—Using bisphosphonates for several years is associated with increasing brittleness and decreasing toughness of bone, according to a new review. “Long-term treatment with bisphosphonates can have negative side effects in some people because of their effects on bone toughness [toughness = the energy that bone tissue can absorb before cracking],” David B….

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesbonebone mineral density (BMD)FracturesOsteoporosisosteoporosis treatments

Abaloparatide vs. Alendronate for Osteoporosis

Lara C. Pullen, PhD  |  August 10, 2020

In a clinical trial, researchers compared the efficacy of abaloparatide with alendronate in reducing the risk of fracture among postmenopausal women with osteoporosis. The findings suggest initial treatment with abaloparatide may result in greater vertebral fracture reduction than alendronate…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:abaloparatidealendronateFracturesOsteoporosisosteoporosis treatments

In Memoriam … J. Timothy Harrington, MD, MACR: July 6, 1940–June 23, 2020

William Arnold, MD; Tim Bartholow, MD; Drew Johnson, MS, MBA; Joel Kremer, MD; Daniel Malone, MD; Eric D. Newman, MD; Kenneth Saag, MD; & Douglas White, MD  |  June 30, 2020

June saw the passing of a beloved colleague, mentor and friend to many in the rheumatology community when J. Timothy Harrington, MD, died of pancreatic cancer in his hometown of Madison, Wis. Dr. Harrington trained at Massachusetts General Hospital, the National Institutes of Health National Cancer Institute and UT Southwestern Medical Center, and served on…

Filed under:Professional TopicsProfiles Tagged with:Dr. J. Timothy HarringtonHarrington

  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 27
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences